{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:37:24Z","timestamp":1791488244997,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01DA04561"],"award-info":[{"award-number":["K01DA04561"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Florida Informatics Institute and Clinical and Translational Science Institute"},{"name":"National Institutes of Health Midcareer Investigator","award":["K24DA034621"],"award-info":[{"award-number":["K24DA034621"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite the availability of efficacious direct-acting antiviral (DAA) therapy, the number of people infected with hepatitis C virus (HCV) continues to rise, and HCV remains a leading cause of liver-related morbidity, liver transplantation, and mortality. We developed and validated machine learning (ML) algorithms to predict DAA treatment failure. Using the HCV-TARGET registry of adults who initiated all-oral DAA treatment, we developed elastic net (EN), random forest (RF), gradient boosting machine (GBM), and feedforward neural network (FNN) ML algorithms. Model performances were compared with multivariable logistic regression (MLR) by assessing C statistics and other prediction evaluation metrics. Among 6525 HCV-infected adults, 308 patients (4.7%) experienced DAA treatment failure. ML models performed similarly in predicting DAA treatment failure (C statistic [95% CI]: EN, 0.74 [0.69\u20130.79]; RF, 0.74 [0.69\u20130.80]; GBM, 0.72 [0.67\u20130.78]; FNN, 0.75 [0.70\u20130.80]), and all 4 outperformed MLR (C statistic [95% CI]: 0.51 [0.46\u20130.57]), and EN used the fewest predictors (n\u2009=\u200927). With Youden index, the EN had 58.4% sensitivity and 77.8% specificity, and nine patients were needed to evaluate to identify 1 DAA treatment failure. Over 60% treatment failure were classified in top three risk decile subgroups. EN-identified predictors included male sex, treatment\u2009&lt;\u20098\u00a0weeks, treatment discontinuation due to adverse events, albumin level\u2009&lt;\u20093.5\u00a0g\/dL, total bilirubin level\u2009&gt;\u20091.2\u00a0g\/dL, advanced liver disease, and use of tobacco, alcohol, or vitamins. Addressing modifiable factors of DAA treatment failure may reduce the burden of retreatment. Machine learning algorithms have the potential to inform public health policies regarding curative treatment of HCV.\n<\/jats:p>","DOI":"10.1038\/s41598-022-22819-4","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T15:22:48Z","timestamp":1666884168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection"],"prefix":"10.1038","volume":"12","author":[{"given":"Haesuk","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hsuan","family":"Lo-Ciganic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sulkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"22819_CR1","unstructured":"Centers for Disease Control and Prevnetion (CDC). Hepatitis C kills more Americans than any other infectious disease. Available at: http:\/\/www.cdc.gov\/media\/releases\/2016\/p0504-hepc-mortality.html. Accessed 10 June 2022."},{"issue":"4","key":"22819_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jhep.2013.11.014","volume":"60","author":"I Ditah","year":"2014","unstructured":"Ditah, I. et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J. Hepatol. 60(4), 691\u2013698 (2014).","journal-title":"J. Hepatol."},{"issue":"5","key":"22819_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.7326\/M13-1133","volume":"160","author":"MM Denniston","year":"2014","unstructured":"Denniston, M. M. et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann. Intern. Med. 160(5), 293\u2013300 (2014).","journal-title":"Ann. Intern. Med."},{"issue":"5 Pt 1","key":"22819_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","volume":"158","author":"RL Morgan","year":"2013","unstructured":"Morgan, R. L. et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: A meta-analysis of observational studies. Ann. Intern. Med. 158(5 Pt 1), 329\u2013337 (2013).","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"22819_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","volume":"156","author":"KN Ly","year":"2012","unstructured":"Ly, K. N. et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann. Intern. Med. 156(4), 271\u2013278 (2012).","journal-title":"Ann. Intern. Med."},{"issue":"9","key":"22819_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/M16-2575","volume":"166","author":"O Falade-Nwulia","year":"2017","unstructured":"Falade-Nwulia, O. et al. Oral direct-acting agent therapy for hepatitis C virus infection: A systematic review. Ann. Intern. Med. 166(9), 637\u2013648 (2017).","journal-title":"Ann. Intern. Med."},{"issue":"14","key":"22819_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.15585\/mmwr.mm6914a2","volume":"69","author":"AB Ryerson","year":"2020","unstructured":"Ryerson, A. B., Schillie, S., Barker, L. K., Kupronis, B. A. & Wester, C. Vital signs: Newly reported acute and chronic hepatitis C cases\u2014United States, 2009\u20132018. MMWR Morb. Mortal. Wkly. Rep. 69(14), 399\u2013404 (2020).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"2","key":"22819_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","volume":"69","author":"S Schillie","year":"2020","unstructured":"Schillie, S., Wester, C., Osborne, M., Wesolowski, L. & Ryerson, A. B. CDC recommendations for hepatitis C screening among adults\u2014United States, 2020. MMWR Recomm. Rep. 69(2), 1\u201317 (2020).","journal-title":"MMWR Recomm. Rep."},{"issue":"RR-4","key":"22819_CR9","first-page":"1","volume":"61","author":"BD Smith","year":"2012","unstructured":"Smith, B. D. et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945\u20131965. MMWR Recomm. Rep. 61(RR-4), 1\u201332 (2012).","journal-title":"MMWR Recomm. Rep."},{"key":"22819_CR10","unstructured":"Centers for Disease Control and Prevnetion (CDC). Viral Hepatitis Surveillance Report. Available at: https:\/\/www.cdc.gov\/hepatitis\/statistics\/2019surveillance\/pdfs\/2019HepSurveillanceRpt.pdf. Accessed 10 June 2022. (2019)."},{"issue":"39","key":"22819_CR11","doi-asserted-by":"publisher","first-page":"833","DOI":"10.15585\/mmwr.mm6839a1","volume":"68","author":"JY Ko","year":"2019","unstructured":"Ko, J. Y., Haight, S. C., Schillie, S. F., Bohm, M. K. & Dietz, P. M. National trends in hepatitis C infection by opioid use disorder status among pregnant women at delivery hospitalization\u2014United States, 2000\u20132015. MMWR Morb. Mortal. Wkly. Rep. 68(39), 833\u2013838 (2019).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"13","key":"22819_CR12","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1056\/NEJMp1716871","volume":"378","author":"TJ Liang","year":"2018","unstructured":"Liang, T. J. & Ward, J. W. Hepatitis C in injection-drug users\u2014A hidden danger of the opioid epidemic. N. Engl. J. Med. 378(13), 1169\u20131171 (2018).","journal-title":"N. Engl. J. Med."},{"key":"22819_CR13","unstructured":"World Health Organization (WHO). Hepatitis C. Available at: http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/. Accessed 10 June 2022."},{"issue":"5","key":"22819_CR14","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/hep.31173","volume":"72","author":"JM Paik","year":"2020","unstructured":"Paik, J. M., Golabi, P., Younossi, Y., Mishra, A. & Younossi, Z. M. Changes in the global burden of chronic liver diseases from 2012 to 2017: The growing impact of NAFLD. Hepatology 72(5), 1605\u20131616 (2020).","journal-title":"Hepatology"},{"key":"22819_CR15","unstructured":"Centers for Disease Control and Prevnetion (CDC). New estimates reveal declines in hepatitis C treatment in the U.S. between 2015 and 2020. Available at: https:\/\/www.cdc.gov\/nchhstp\/newsroom\/2021\/2014-2020-hepatitis-c-treatment-estimates.html. Accessed 10 June 2022."},{"issue":"10179","key":"22819_CR16","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/S0140-6736(18)32326-2","volume":"393","author":"JA Holmes","year":"2019","unstructured":"Holmes, J. A., Rutledge, S. M. & Chung, R. T. Direct-acting antiviral treatment for hepatitis C. Lancet 393(10179), 1392\u20131394 (2019).","journal-title":"Lancet"},{"issue":"6","key":"22819_CR17","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1002\/hep.29693","volume":"67","author":"PR Harrington","year":"2018","unstructured":"Harrington, P. R. et al. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives. Hepatology 67(6), 2430\u20132448 (2018).","journal-title":"Hepatology"},{"key":"22819_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32347","author":"H Park","year":"2022","unstructured":"Park, H. et al. Machine learning algorithms for predicting direct-acting antiviral treatment failure in chronic hepatitis C: An HCV-TARGET analysis. Hepatology https:\/\/doi.org\/10.1002\/hep.32347 (2022).","journal-title":"Hepatology"},{"issue":"3","key":"22819_CR19","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1053\/j.gastro.2017.07.025","volume":"153","author":"P Mishra","year":"2017","unstructured":"Mishra, P. et al. Public-private partnership: Targeting real-world data for hepatitis C direct-acting antivirals. Gastroenterology 153(3), 626\u2013631 (2017).","journal-title":"Gastroenterology"},{"issue":"3","key":"22819_CR20","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1148\/radiol.2015151516","volume":"277","author":"PM Bossuyt","year":"2015","unstructured":"Bossuyt, P. M. et al. STARD 2015: An updated list of essential items for reporting diagnostic accuracy studies. Radiology 277(3), 826\u2013832 (2015).","journal-title":"Radiology"},{"issue":"9","key":"22819_CR21","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1080\/14656566.2016.1182156","volume":"17","author":"L Benitez-Gutierrez","year":"2016","unstructured":"Benitez-Gutierrez, L. et al. Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin. Pharmacother. 17(9), 1215\u20131223 (2016).","journal-title":"Expert Opin. Pharmacother."},{"issue":"10","key":"22819_CR22","doi-asserted-by":"publisher","first-page":"e0185728","DOI":"10.1371\/journal.pone.0185728","volume":"12","author":"LA Kondili","year":"2017","unstructured":"Kondili, L. A. et al. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS ONE 12(10), e0185728 (2017).","journal-title":"PLoS ONE"},{"issue":"6","key":"22819_CR23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/MEG.0000000000000858","volume":"29","author":"F Su","year":"2017","unstructured":"Su, F., Beste, L. A., Green, P. K., Berry, K. & Ioannou, G. N. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: A real-world study of 17 487 patients. Eur. J. Gastroenterol. Hepatol. 29(6), 686\u2013693 (2017).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"22819_CR24","unstructured":"Hastie T. T.R., Friedman J. The Elements of statistical learning: data mining, inference and prediction. New York, NY (2008)."},{"issue":"3","key":"22819_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.artmed.2007.10.003","volume":"42","author":"A Chu","year":"2008","unstructured":"Chu, A. et al. A decision support system to facilitate management of patients with acute gastrointestinal bleeding. Artif. Intell. Med. 42(3), 247\u2013259 (2008).","journal-title":"Artif. Intell. Med."},{"issue":"6","key":"22819_CR26","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1053\/j.gastro.2016.08.004","volume":"151","author":"NA Terrault","year":"2016","unstructured":"Terrault, N. A. et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology 151(6), 1131\u20131134 (2016).","journal-title":"Gastroenterology"},{"issue":"3","key":"22819_CR27","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 44(3), 837\u2013845 (1988).","journal-title":"Biometrics"},{"issue":"4","key":"22819_CR28","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/bimj.200410135","volume":"47","author":"R Fluss","year":"2005","unstructured":"Fluss, R., Faraggi, D. & Reiser, B. Estimation of the Youden Index and its associated cutoff point. Biom. J. 47(4), 458\u2013472 (2005).","journal-title":"Biom. J."},{"key":"22819_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32347","author":"HL-CW Park","year":"2022","unstructured":"Park, H.L.-C.W. et al. Machine learning algorithms for predicting direct-acting antiviral treatment failure in chronic hepatitis C: An HCV-TARGET analysis. Hepatology https:\/\/doi.org\/10.1002\/hep.32347 (2022).","journal-title":"Hepatology"},{"issue":"1","key":"22819_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11901-010-0078-7","volume":"10","author":"H Sung","year":"2011","unstructured":"Sung, H., Chang, M. & Saab, S. Management of hepatitis C antiviral therapy adverse effects. Curr. Hepat. Rep. 10(1), 33\u201340 (2011).","journal-title":"Curr. Hepat. Rep."},{"issue":"6","key":"22819_CR31","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.amjmed.2018.01.011","volume":"131","author":"RS Kim","year":"2018","unstructured":"Kim, R. S. et al. Cigarette smoking in persons living with hepatitis C: The National Health and Nutrition Examination Survey (NHANES), 1999\u20132014. Am. J. Med. 131(6), 669\u2013675 (2018).","journal-title":"Am. J. Med."},{"issue":"10","key":"22819_CR32","doi-asserted-by":"publisher","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","volume":"144","author":"GL Armstrong","year":"2006","unstructured":"Armstrong, G. L. et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 144(10), 705\u2013714 (2006).","journal-title":"Ann. Intern. Med."},{"key":"22819_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.drugalcdep.2016.10.021","volume":"169","author":"JI Tsui","year":"2016","unstructured":"Tsui, J. I. et al. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend. 169, 101\u2013109 (2016).","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"22819_CR34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1055\/s-0031-1297927","volume":"31","author":"JA Gutierrez","year":"2011","unstructured":"Gutierrez, J. A., Parikh, N. & Branch, A. D. Classical and emerging roles of vitamin D in hepatitis C virus infection. Semin. Liver Dis. 31(4), 387\u2013398 (2011).","journal-title":"Semin. Liver Dis."},{"issue":"3","key":"22819_CR35","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/hep.26186","volume":"57","author":"D Bitetto","year":"2013","unstructured":"Bitetto, D. et al. Vitamin A deficiency is associated with hepatitis C virus chronic infection and with unresponsiveness to interferon-based antiviral therapy. Hepatology 57(3), 925\u2013933 (2013).","journal-title":"Hepatology"},{"issue":"7","key":"22819_CR36","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/MEG.0000000000001134","volume":"30","author":"CN Jin","year":"2018","unstructured":"Jin, C. N., Chen, J. D. & Sheng, J. F. Vitamin D deficiency in hepatitis C virus infection: What is old? What is new?. Eur. J. Gastroenterol. Hepatol. 30(7), 741\u2013746 (2018).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"4","key":"22819_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.14740\/gr1072w","volume":"11","author":"V Gayam","year":"2018","unstructured":"Gayam, V. et al. Association between vitamin D levels and treatment response to direct-acting antivirals in chronic hepatitis C: A real-world study. Gastroenterol. Res. 11(4), 309\u2013316 (2018).","journal-title":"Gastroenterol. Res."},{"issue":"5","key":"22819_CR38","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4254\/wjh.v9.i5.278","volume":"9","author":"AS Dadabhai","year":"2017","unstructured":"Dadabhai, A. S., Saberi, B., Lobner, K., Shinohara, R. T. & Mullin, G. E. Influence of vitamin D on liver fibrosis in chronic hepatitis C: A systematic review and meta-analysis of the pooled clinical trials data. World J. Hepatol. 9(5), 278\u2013287 (2017).","journal-title":"World J. Hepatol."},{"issue":"3","key":"22819_CR39","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","volume":"151","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin, C. et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology 151(3), 501\u201312 e1 (2016).","journal-title":"Gastroenterology"},{"issue":"6","key":"22819_CR40","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1053\/j.gastro.2019.08.008","volume":"157","author":"AS Lok","year":"2019","unstructured":"Lok, A. S. et al. Efficacy of glecaprevir and pibrentasvir in patients with genotype 1 hepatitis C virus infection with treatment failure after NS5A inhibitor plus sofosbuvir therapy. Gastroenterology 157(6), 1506\u201317 e1 (2019).","journal-title":"Gastroenterology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22819-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22819-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22819-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T15:38:37Z","timestamp":1666885117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22819-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["22819"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-22819-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"assertion":[{"value":"14 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HP received grant funding from Bristol-Myers Squibb\/Pfizer Alliance American Thrombosis Investigator Initiated Research Program (ARISTA-USA). WL received research funding from Merck & Co. DRN received research grant support from AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Merck & Co; and owns stock in Target Pharma Solutions. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18094"}}